Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)

3. august 2011 opdateret af: Pfizer

A Randomized Phase II Study Of The Efficacy And Safety Of Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (Renal EFFECT Trial)

This trial has two parts. The purpose of the first part of the trial is to determine the doses of 2 drugs, sunitinib malate and interferon alfa-2b, that can be given safely in combination. This part is currently closed to enrollment.

The purpose of the second part of the trial is to see if sunitinib malate given on a 4/2 schedule (4 weeks on treatment, 2 weeks off treatment cycle) is any better at delaying progression of renal cell cancer than sunitinib malate given on a continuous dosing schedule. The trial will also determine the number of patients whose cancer responds to the treatments, whether life of patients can be extended, what the side effects are of the treatments, how bothersome disease or treatment-related symptoms are to patients, and whether tests can be found that will predict which patients may or may not respond to these treatments in the future.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

317

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Forenede Stater
    • Arkansas
      • Hot Springs, Arkansas, Forenede Stater, 71913
        • Pfizer Investigational Site
      • Little Rock, Arkansas, Forenede Stater, 72205
        • Pfizer Investigational Site
    • California
      • Anaheim, California, Forenede Stater, 92807
        • Pfizer Investigational Site
      • Baldwin Park, California, Forenede Stater, 91706
        • Pfizer Investigational Site
      • Bellflower, California, Forenede Stater, 90706
        • Pfizer Investigational Site
      • Duarte, California, Forenede Stater, 91010
        • Pfizer Investigational Site
      • Fontana, California, Forenede Stater, 92335
        • Pfizer Investigational Site
      • Irvine, California, Forenede Stater, 92618
        • Pfizer Investigational Site
      • Los Angeles, California, Forenede Stater, 90095
        • Pfizer Investigational Site
      • Los Angeles, California, Forenede Stater, 90027
        • Pfizer Investigational Site
      • Los Angeles, California, Forenede Stater, 90034
        • Pfizer Investigational Site
      • Panorama City, California, Forenede Stater, 91402
        • Pfizer Investigational Site
      • Riverside, California, Forenede Stater, 92505
        • Pfizer Investigational Site
      • San Diego, California, Forenede Stater, 92108
        • Pfizer Investigational Site
      • San Diego, California, Forenede Stater, 92120
        • Pfizer Investigational Site
      • Woodland Hills, California, Forenede Stater, 91365
        • Pfizer Investigational Site
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80012
        • Pfizer Investigational Site
      • Boulder, Colorado, Forenede Stater, 80304
        • Pfizer Investigational Site
      • Boulder, Colorado, Forenede Stater, 80303
        • Pfizer Investigational Site
      • Colorado Springs, Colorado, Forenede Stater, 80909
        • Pfizer Investigational Site
      • Denver, Colorado, Forenede Stater, 80220
        • Pfizer Investigational Site
      • Denver, Colorado, Forenede Stater, 80218
        • Pfizer Investigational Site
      • Lakewood, Colorado, Forenede Stater, 80228
        • Pfizer Investigational Site
      • Littleton, Colorado, Forenede Stater, 80120
        • Pfizer Investigational Site
      • Lone Tree, Colorado, Forenede Stater, 80124
        • Pfizer Investigational Site
      • Longmont, Colorado, Forenede Stater, 80501
        • Pfizer Investigational Site
      • Parker, Colorado, Forenede Stater, 80138
        • Pfizer Investigational Site
      • Pueblo, Colorado, Forenede Stater, 81008
        • Pfizer Investigational Site
      • Thorton, Colorado, Forenede Stater, 80260
        • Pfizer Investigational Site
    • Connecticut
      • Norwich, Connecticut, Forenede Stater, 06360
        • Pfizer Investigational Site
    • Delaware
      • Newark, Delaware, Forenede Stater, 19718
        • Pfizer Investigational Site
      • Newark, Delaware, Forenede Stater, 19713
        • Pfizer Investigational Site
      • Wilmington, Delaware, Forenede Stater, 19899
        • Pfizer Investigational Site
    • Florida
      • Boca Raton, Florida, Forenede Stater, 33486
        • Pfizer Investigational Site
      • Delray Beach, Florida, Forenede Stater, 33484
        • Pfizer Investigational Site
      • Lakeland, Florida, Forenede Stater, 33805
        • Pfizer Investigational Site
      • Orlando, Florida, Forenede Stater, 32806
        • Pfizer Investigational Site
    • Georgia
      • Columbus, Georgia, Forenede Stater, 31902
        • Pfizer Investigational Site
      • Columbus, Georgia, Forenede Stater, 31904
        • Pfizer Investigational Site
    • Idaho
      • Boise, Idaho, Forenede Stater, 83712
        • Pfizer Investigational Site
    • Indiana
      • Elkhart, Indiana, Forenede Stater, 46514
        • Pfizer Investigational Site
      • Jefferson, Indiana, Forenede Stater, 47130
        • Pfizer Investigational Site
      • Kokomo, Indiana, Forenede Stater, 46902-3803
        • Pfizer Investigational Site
      • La Porte, Indiana, Forenede Stater, 46350
        • Pfizer Investigational Site
      • LaPorte, Indiana, Forenede Stater, 46350
        • Pfizer Investigational Site
      • LaPorte, Indiana, Forenede Stater, 46350-5533
        • Pfizer Investigational Site
      • Michigan City, Indiana, Forenede Stater, 46360
        • Pfizer Investigational Site
      • Plymouth, Indiana, Forenede Stater, 46563
        • Pfizer Investigational Site
      • South Bend, Indiana, Forenede Stater, 46601
        • Pfizer Investigational Site
      • South Bend, Indiana, Forenede Stater, 46617
        • Pfizer Investigational Site
    • Iowa
      • Cedar Rapids, Iowa, Forenede Stater, 52402
        • Pfizer Investigational Site
    • Kentucky
      • Lexington, Kentucky, Forenede Stater, 40536
        • Pfizer Investigational Site
      • Lexington, Kentucky, Forenede Stater, 40536-0293
        • Pfizer Investigational Site
      • Louisville, Kentucky, Forenede Stater, 40202
        • Pfizer Investigational Site
      • Louisville, Kentucky, Forenede Stater, 40217
        • Pfizer Investigational Site
      • Louisville, Kentucky, Forenede Stater, 40207
        • Pfizer Investigational Site
      • Shelbyville, Kentucky, Forenede Stater, 40065
        • Pfizer Investigational Site
    • Louisiana
      • Baton Rouge, Louisiana, Forenede Stater, 70809
        • Pfizer Investigational Site
      • Covington, Louisiana, Forenede Stater, 70433
        • Pfizer Investigational Site
      • Gretna, Louisiana, Forenede Stater, 70056
        • Pfizer Investigational Site
      • Marrero, Louisiana, Forenede Stater, 70072
        • Pfizer Investigational Site
      • Metairie, Louisiana, Forenede Stater, 70006
        • Pfizer Investigational Site
      • New Orleans, Louisiana, Forenede Stater, 70115
        • Pfizer Investigational Site
      • Shreveport, Louisiana, Forenede Stater, 71103
        • Pfizer Investigational Site
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21201
        • Pfizer Investigational Site
      • Baltimore, Maryland, Forenede Stater, 21237
        • Pfizer Investigational Site
      • Bethesda, Maryland, Forenede Stater, 20817
        • Pfizer Investigational Site
    • Michigan
      • Grand Rapids, Michigan, Forenede Stater, 49503
        • Pfizer Investigational Site
      • Holland, Michigan, Forenede Stater, 49424
        • Pfizer Investigational Site
      • Niles, Michigan, Forenede Stater, 49120
        • Pfizer Investigational Site
      • Saint Joseph, Michigan, Forenede Stater, 49085
        • Pfizer Investigational Site
      • St. Joseph, Michigan, Forenede Stater, 49085
        • Pfizer Investigational Site
      • St. Joseph, Michigan, Forenede Stater, 49085-2112
        • Pfizer Investigational Site
      • St. Joseph, Michigan, Forenede Stater, 49085-2158
        • Pfizer Investigational Site
    • Missouri
      • Saint Louis, Missouri, Forenede Stater, 63141
        • Pfizer Investigational Site
      • St. Louis, Missouri, Forenede Stater, 63141
        • Pfizer Investigational Site
      • Washington, Missouri, Forenede Stater, 63090
        • Pfizer Investigational Site
    • Nevada
      • Henderson, Nevada, Forenede Stater, 89052
        • Pfizer Investigational Site
      • Las Vegas, Nevada, Forenede Stater, 89128
        • Pfizer Investigational Site
      • Las Vegas, Nevada, Forenede Stater, 89148
        • Pfizer Investigational Site
      • Las Vegas, Nevada, Forenede Stater, 89135
        • Pfizer Investigational Site
      • Las Vegas, Nevada, Forenede Stater, 89169
        • Pfizer Investigational Site
    • New Jersey
      • Hackensack, New Jersey, Forenede Stater, 07601
        • Pfizer Investigational Site
    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 87131-0001
        • Pfizer Investigational Site
      • Farmington, New Mexico, Forenede Stater, 87401-5631
        • Pfizer Investigational Site
    • New York
      • Albany, New York, Forenede Stater, 12206
        • Pfizer Investigational Site
      • Albany, New York, Forenede Stater, 12208
        • Pfizer Investigational Site
      • Amsterdam, New York, Forenede Stater, 12010
        • Pfizer Investigational Site
      • Brockport, New York, Forenede Stater, 14420
        • Pfizer Investigational Site
      • Canadaigua, New York, Forenede Stater, 14424
        • Pfizer Investigational Site
      • Geneva, New York, Forenede Stater, 14456
        • Pfizer Investigational Site
      • Hudson, New York, Forenede Stater, 12534
        • Pfizer Investigational Site
      • Latham, New York, Forenede Stater, 12110
        • Pfizer Investigational Site
      • New York, New York, Forenede Stater, 10021
        • Pfizer Investigational Site
      • New York, New York, Forenede Stater, 10032
        • Pfizer Investigational Site
      • New York, New York, Forenede Stater, 10022
        • Pfizer Investigational Site
      • Rexford, New York, Forenede Stater, 12148
        • Pfizer Investigational Site
      • Rochester, New York, Forenede Stater, 14623
        • Pfizer Investigational Site
      • Rochester, New York, Forenede Stater, 14626
        • Pfizer Investigational Site
      • Troy, New York, Forenede Stater, 12180
        • Pfizer Investigational Site
    • North Carolina
      • Cary, North Carolina, Forenede Stater, 27518
        • Pfizer Investigational Site
      • Clinton, North Carolina, Forenede Stater, 28328
        • Pfizer Investigational Site
      • Elizabeth City, North Carolina, Forenede Stater, 27909
        • Pfizer Investigational Site
      • Goldsboro, North Carolina, Forenede Stater, 27534
        • Pfizer Investigational Site
      • Hickory, North Carolina, Forenede Stater, 28602
        • Pfizer Investigational Site
      • Raleigh, North Carolina, Forenede Stater, 27607
        • Pfizer Investigational Site
      • Raleigh, North Carolina, Forenede Stater, 27614
        • Pfizer Investigational Site
      • Wilson, North Carolina, Forenede Stater, 27893
        • Pfizer Investigational Site
    • Ohio
      • Canton, Ohio, Forenede Stater, 44718
        • Pfizer Investigational Site
      • Columbus, Ohio, Forenede Stater, 43219
        • Pfizer Investigational Site
    • Oklahoma
      • Norman, Oklahoma, Forenede Stater, 73071
        • Pfizer Investigational Site
      • Oklahoma City, Oklahoma, Forenede Stater, 73120
        • Pfizer Investigational Site
      • Oklahoma City, Oklahoma, Forenede Stater, 73102
        • Pfizer Investigational Site
      • Oklahoma City, Oklahoma, Forenede Stater, 73109
        • Pfizer Investigational Site
      • Oklahoma City, Oklahoma, Forenede Stater, 73112-4416
        • Pfizer Investigational Site
      • Tulsa, Oklahoma, Forenede Stater, 74133
        • Pfizer Investigational Site
      • Tulsa, Oklahoma, Forenede Stater, 74104
        • Pfizer Investigational Site
      • Tulsa, Oklahoma, Forenede Stater, 74136-1902
        • Pfizer Investigational Site
    • Oregon
      • Eugene, Oregon, Forenede Stater, 97401
        • Pfizer Investigational Site
      • Springfield, Oregon, Forenede Stater, 97477
        • Pfizer Investigational Site
    • Pennsylvania
      • Dunmore, Pennsylvania, Forenede Stater, 18512-3169
        • Pfizer Investigational Site
      • Lemoyne, Pennsylvania, Forenede Stater, 17043-1440
        • Pfizer Investigational Site
      • Philadelphia, Pennsylvania, Forenede Stater, 19111-2497
        • Pfizer Investigational Site
      • Scranton, Pennsylvania, Forenede Stater, 18508
        • Pfizer Investigational Site
    • South Carolina
      • Easley, South Carolina, Forenede Stater, 29640
        • Pfizer Investigational Site
      • Greenville, South Carolina, Forenede Stater, 29615
        • Pfizer Investigational Site
      • Greenville, South Carolina, Forenede Stater, 29605
        • Pfizer Investigational Site
      • Seneca, South Carolina, Forenede Stater, 29672
        • Pfizer Investigational Site
      • Spartanburg, South Carolina, Forenede Stater, 29307
        • Pfizer Investigational Site
    • Texas
      • Austin, Texas, Forenede Stater, 78705
        • Pfizer Investigational Site
      • Austin, Texas, Forenede Stater, 78745
        • Pfizer Investigational Site
      • Austin, Texas, Forenede Stater, 78759
        • Pfizer Investigational Site
      • Austin, Texas, Forenede Stater, 78731
        • Pfizer Investigational Site
      • Austin, Texas, Forenede Stater, 78758
        • Pfizer Investigational Site
      • Bedford, Texas, Forenede Stater, 76022
        • Pfizer Investigational Site
      • Corpus Christi, Texas, Forenede Stater, 78463
        • Pfizer Investigational Site
      • Dallas, Texas, Forenede Stater, 75230
        • Pfizer Investigational Site
      • Dallas, Texas, Forenede Stater, 75246
        • Pfizer Investigational Site
      • Fort Worth, Texas, Forenede Stater, 76177
        • Pfizer Investigational Site
      • Georgetown, Texas, Forenede Stater, 78626
        • Pfizer Investigational Site
      • Round Rock, Texas, Forenede Stater, 78681
        • Pfizer Investigational Site
      • San Antonio, Texas, Forenede Stater, 78229
        • Pfizer Investigational Site
      • San Antonio, Texas, Forenede Stater, 78207
        • Pfizer Investigational Site
      • San Antonio, Texas, Forenede Stater, 78217
        • Pfizer Investigational Site
      • San Antonio, Texas, Forenede Stater, 78258
        • Pfizer Investigational Site
      • Tyler, Texas, Forenede Stater, 75702
        • Pfizer Investigational Site
      • Webster, Texas, Forenede Stater, 77598
        • Pfizer Investigational Site
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84112
        • Pfizer Investigational Site
    • Virginia
      • Chesapeake, Virginia, Forenede Stater, 23320
        • Pfizer Investigational Site
      • Hampton, Virginia, Forenede Stater, 23666
        • Pfizer Investigational Site
      • Newport News, Virginia, Forenede Stater, 23601
        • Pfizer Investigational Site
      • Newport News, Virginia, Forenede Stater, 23502
        • Pfizer Investigational Site
      • Norfolk, Virginia, Forenede Stater, 23502
        • Pfizer Investigational Site
      • Virginia Beach, Virginia, Forenede Stater, 23456
        • Pfizer Investigational Site
      • Williamsburg, Virginia, Forenede Stater, 23188
        • Pfizer Investigational Site
    • Washington
      • Seattle, Washington, Forenede Stater, 98195
        • Pfizer Investigational Site
      • Seattle, Washington, Forenede Stater, 98109
        • Pfizer Investigational Site
    • West Virginia
      • Morgantown, West Virginia, Forenede Stater, 26506
        • Pfizer Investigational Site
    • Wisconsin
      • Madison, Wisconsin, Forenede Stater, 53792
        • Pfizer Investigational Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Advanced renal cell carcinoma of clear cell origin or a component of clear cell histology.
  • Measurable disease

Exclusion Criteria:

  • Prior systemic therapy of any kind for advanced renal cell cancer
  • History of brain metastases
  • Uncontrolled hypertension

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: EN
Medicin: Sunitinib Malate Schedule 4/2
Sunitinib malate starting dose 50 mg per day for four weeks, followed by a two week off-drug period. This six week cycle is repeated.
Eksperimentel: C
Medicin: Sunitinib Malate Continuous Daily Dosing
Sunitinib malate starting dose 37.5 mg daily continuous daily regimen.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to Tumor Progression (TTP) Assessed Using Memorial Sloan-Kettering Cancer Center (MSKCC) Prognostic Factors Model
Tidsramme: From date of randomization until the date of first documented progression or date of death due to any cause, assessed up to a maximum of 2 years
MSKCC Prognostic Factor Model assessed as low(0),intermediate(1-2) or high(=>3) based on number of criteria present such as Karnofsky performance status < 80 %, Lactate dehydrogenase > 1.5 * Upper limit of Normal,Hemoglobin < lower limit of normal, serum calcium > 10 mg/dL;Time from first diagnosis of renal cell carcinoma to start of systemic therapy of < 1 year.TTP was time from start of study treatment to first documentation of objective tumor progression or death due to cancer.TTP was calculated as (first event date minus date of first dose of study medication plus 1) divided by 30.44.
From date of randomization until the date of first documented progression or date of death due to any cause, assessed up to a maximum of 2 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Participants With Objective Response (OR)
Tidsramme: From date of randomization until the date of first documented progression or date of death due to any cause, assessed up to a maximum of 2 years
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with atleast 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
From date of randomization until the date of first documented progression or date of death due to any cause, assessed up to a maximum of 2 years
Duration of Response (DR)
Tidsramme: From date of randomization until the date of first documented progression or date of death due to any cause, assessed up to a maximum of 2 years
Time from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.44. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
From date of randomization until the date of first documented progression or date of death due to any cause, assessed up to a maximum of 2 years
Overall Survival (OS) Assessed Using MSKCC Prognostic Factors Model
Tidsramme: From date of randomization until the date of first documented progression or date of death due to any cause, assessed up to a maximum of 2 years
MSKCC Prognostic Factor Model assessed as low (0), intermediate (1-2) or high (=>3) based upon number of criteria present. Criteria as follows: Karnofsky performance status < 80 %, Lactate dehydrogenase > 1.5 * Upper limit of Normal, Hemoglobin < lower limit of normal for local lab, Corrected serum calcium > 10 mg/dL; Time from first diagnosis of renal cell carcinoma to start of systemic therapy of < 1 year. OS was defined as time from date of start of treatment to date of death due to any cause. OS, in months, was calculated as (event date -start of treatment date + 1)/30.44.
From date of randomization until the date of first documented progression or date of death due to any cause, assessed up to a maximum of 2 years

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Functional Assessment of Cancer Therapy-General (FACT-G)
Tidsramme: From date of randomization until the date of first documented progression or date of death due to any cause, assessed up to a maximum of 2 years
FACT-G is core questionnaire of Functional Assessment of Chronic Illness Therapy (FACIT) measurement system to evaluate quality of life (QoL) in cancer population.FACT-G consisted of 27 questions grouped in 4 domains of general Health-Related QoL(HRQoL):Physical Well-being(PWB),Social/Family Well-Being (SWB),Emotional Well-Being (EWB) and Functional Well-Being (FWB);each ranging from 0 (not at all) to 4 (very much) so that FACT-G ranged between 0-108.Since questions could be reversed coded, as appropriate, before calculating FACT-G,0 and 108 could be considered worst and best health states.
From date of randomization until the date of first documented progression or date of death due to any cause, assessed up to a maximum of 2 years
FACT-Kidney Symptom Index for Disease Related Symptoms (FKSI-DRS)
Tidsramme: From date of randomization until the date of first documented progression or date of death due to any cause, assessed up to a maximum of 2 years

FKSI-DRS is a subset of FKSI which is a questionnaire for Functional Assessment of Cancer Therapy -Kidney Symptom Index used to assess QoL/participant-reported outcomes for participants diagnosed with renal cell cancer.

The FKSI contained 15 questions and the FKSI-DRS consisted of 9 questions each ranging from 0 (not at all) to 4 (very much) so that FKSI-DRS ranged between 0-36. Since the questions could be reversed coded, as appropriate, before calculating FKSI-DRS, 0 and 36 could be considered the worst and best health states based on the 9 questions comprising FKSI-DRS.
From date of randomization until the date of first documented progression or date of death due to any cause, assessed up to a maximum of 2 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Pfizer

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. december 2005

Primær færdiggørelse (Faktiske)

1. juni 2010

Studieafslutning (Faktiske)

1. juni 2010

Datoer for studieregistrering

Først indsendt

20. december 2005

Først indsendt, der opfyldte QC-kriterier

20. december 2005

Først opslået (Skøn)

21. december 2005

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

5. september 2011

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. august 2011

Sidst verificeret

1. august 2011

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • A6181065

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner